FDA, FTC join forces to increase biosimilar availability

(By Maia Anderson for Becker’s Hospital Review)

The Federal Trade Commission and FDA issued a joint statement outlining steps the two agencies plan to boost competition in the biologic drug market.

Biologic drugs are made from living cells and treat many serious illnesses, including rare genetic disorders, autoimmune diseases and cancer. They’re typically very expensive, and the U.S. spent $125.5 billion on biologics in 2018 alone.   Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.